TL;DR
This study identifies two novel plasma protein biomarkers, F5 and PROZ, that can predict chemotherapy resistance in patients with advanced colorectal cancer (CRC). By combining proteomic profiling with circulating tumor cell (CTC) drug susceptibility testing, the researchers found these proteins to be significantly elevated in patients who did not respond well to treatment, offering a potential tool for personalized medicine.
What Problem Does This Paper Address?
Colorectal cancer (CRC) remains a significant global health challenge, and for patients with advanced stages, chemotherapy is often the primary treatment option. However, a major hurdle is primary drug resistance, where tumors inherently don't respond to chemotherapy, leading to poor outcomes and immense patient distress. Predicting this resistance upfront is crucial for effective treatment planning and avoiding ineffective therapies. While plasma protein profiles have shown promise as diagnostic and prognostic markers, identifying specific biomarkers for chemotherapy resistance in CRC has remained an unmet need. This paper aims to fill that gap by exploring plasma proteome changes associated with chemotherapy resistance.
Methods
The researchers employed a multi-pronged approach:
- Automated Plasma Proteome Profiling: They utilized an automated sample preparation workflow coupled with high-throughput LC-MS/MS (liquid chromatography-tandem mass spectrometry) to analyze plasma proteins from CRC patients. This method was chosen for its robustness and reproducibility.
- Circulating Tumor Cell (CTC) Drug Susceptibility Testing: This technique assesses how well tumor cells from a patient's blood respond to various chemotherapy drugs. The idea is that CTC behavior in vitro can reflect in vivo drug response.
- Correlation Analysis: They correlated the identified plasma protein levels with the results of CTC drug susceptibility testing to find proteins associated with drug resistance.
- Chemotherapy Outcome Classification: Patients were categorized into three groups based on their treatment response: Objective Response (OR), Stable Disease (SD), and Progressive Disease (PD). Differential protein expression between these groups was analyzed.
- Enzyme-Linked Immunosorbent Assay (ELISA): Promising candidate biomarkers identified through MS were validated using ELISA in a separate cohort of patients.
Datasets
- Plasma samples from 139 advanced CRC patients: These were collected from Shenzhen People's Hospital.
- 60 samples were used for initial proteomic profiling and correlation with CTC drug susceptibility.
- 44 samples served as a "test cohort" for analyzing differential protein expression based on chemotherapy outcomes.
- 79 samples formed a "validation cohort" for ELISA-based confirmation of candidate biomarkers.
- Proteomic datasets: Available at iProX website with the dataset identifier PXD043974.
Key Insights and Ideas
- CTC drug susceptibility as a proxy for resistance: The study leverages CTC drug susceptibility testing as a valuable tool to predict chemotherapy outcomes, bridging the gap between in vitro drug response and clinical prognosis.
- Plasma proteome as a rich source of biomarkers: The research reinforces the utility of plasma proteomics for discovering clinically relevant biomarkers, even for complex conditions like chemotherapy resistance.
- F5 and PROZ as novel resistance indicators: The identification of F5 and PROZ as significantly upregulated in resistant CRC patients is a key finding, suggesting their potential as predictive biomarkers.
- Coagulation cascade link to resistance: The involvement of F5 (coagulation factor V) and PROZ (protein Z-dependent protein inhibitor) in the coagulation cascade, and their association with cancer development, highlights a potential mechanistic link between hemostasis and chemotherapy resistance.
Key Results
- 85 proteins correlated with drug resistance: Analysis of plasma proteome and CTC drug susceptibility testing identified 85 proteins showing significant positive or negative correlations with chemotherapy resistance.
- 37 differentially expressed proteins in outcome groups: Comparing patients with different chemotherapy outcomes (OR, SD, PD) revealed 37 differentially expressed proteins.
- F5 and PROZ significantly elevated in resistant patients: Through validation with ELISA, F5 and PROZ protein levels were found to be markedly increased in the Progressive Disease (PD) group, indicating chemotherapy resistance, compared to the SD and OR groups.
- High reproducibility of the workflow: The automated sample preparation and LC-MS/MS workflow demonstrated high reproducibility, with Pearson correlation coefficients ranging from 0.989 to 0.998 and low coefficients of variation (CVs).
Limitations and Future Work
- Sample size limitations: The authors acknowledge that the test and validation cohorts were not large enough, and the sex ratio of patients was not strictly comparable.
- Further validation needed: While F5 and PROZ showed promising results, larger, prospective studies are needed to fully establish their clinical utility.
- Mechanistic exploration: Further research could delve deeper into the precise mechanisms by which F5 and PROZ contribute to chemotherapy resistance in CRC.
- Broader application: Investigating these biomarkers in other cancer types or treatment regimens could expand their applicability.
Summary updated